First Capital Treasuries PLC (COSE:FCT.N0000)

Ligand Pharmaceuticals Income Statement

Financials in millions LKR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Interest and Dividend Income	7,746	10,788	9,903	1,528	1,825
Net Interest Income	7,746	10,788	9,903	1,528	1,825
Gain on Sale of Investments (Rev)	3,719	15,504	1,144	-978.7	2,084
Other Revenue	53.16	8.29	5.1	0.07	-
Revenue	11,518	26,299	11,053	549.05	3,909
Revenue Growth (YoY)	-56.21%	137.94%	1913.10%	-85.95%	-4.00%
Salaries & Employee Benefits	297.29	1,642	443.48	110.89	324.08
Cost of Services Provided	6,258	7,982	6,331	1,089	1,336
Other Operating Expenses	491.12	638.32	525.23	293.85	57.52
Total Operating Expenses	7,047	10,262	7,300	1,494	1,718
Operating Income	4,471	16,038	3,753	-944.63	2,191
Currency Exchange Gains	-	-	0.04	54.92	206.83
EBT Excluding Unusual Items	4,471	16,038	3,753	-889.71	2,397
Pretax Income	4,472	16,038	3,753	-889.7	2,397
Income Tax Expense	1,430	4,895	866.51	-237.25	560.06
Net Income	3,042	11,143	2,886	-652.45	1,837
Net Income to Common	3,042	11,143	2,886	-652.45	1,837
Net Income Growth	-72.70%	286.06%	-	-	52.15%
Shares Outstanding (Basic)	616	616	616	616	616
Shares Outstanding (Diluted)	616	616	616	616	616
EPS (Basic)	4.94	18.10	4.69	-1.06	2.98
EPS (Diluted)	4.94	18.10	4.69	-1.06	2.98
EPS Growth	-72.70%	286.06%	-	-	52.15%
Free Cash Flow	5,508	7,086	-324.47	202.03	1,193
Free Cash Flow Per Share	8.95	11.51	-0.53	0.33	1.94
Dividend Per Share	2.600	14.500	1.500	-	0.840
Dividend Growth	-82.07%	866.67%	-	-	-34.76%
Operating Margin	38.82%	60.98%	33.95%	-172.05%	56.04%
Profit Margin	26.41%	42.37%	26.11%	-118.83%	47.01%
Free Cash Flow Margin	47.82%	26.95%	-2.94%	36.80%	30.52%
Effective Tax Rate	31.97%	30.52%	23.09%	-	23.36%
Revenue as Reported	5,353	18,406	-	-	-

Source: S&P Global Market Intelligence. Capital Markets template. Financial Sources.